{
    "info": {
        "nct_id": "NCT02872714",
        "official_title": "A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations - (FIGHT-201)",
        "inclusion_criteria": "* 20 years and older in Japan\n* Histologically documented metastatic or surgically unresectable urothelial carcinoma; may include primary site from urethra, ureters, upper tract, renal pelvis, and bladder.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Life expectancy ≥ 12 weeks.\n* Radiographically measurable per RECIST v1.1.\n* Documented FGF/FGFR alteration and have either 1a) failed at least 1 previous treatment for their metastatic or surgically unresectable urothelial carcinoma (ie, chemotherapy, immunotherapy) or 1b) have not received chemotherapy due to poor ECOG status or 2) have insufficient renal function.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Prior receipt of a selective FGFR inhibitor.\n* Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half-lives (whichever is shorter) before the first dose of study drug.\n* Inability or unwillingness to swallow pemigatinib or significant gastrointestinal disorder(s) that could interfere with the absorption, metabolism, or excretion of pemigatinib.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Life expectancy ≥ 12 weeks.",
                "criterions": [
                    {
                        "exact_snippets": "Life expectancy ≥ 12 weeks.",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Life expectancy ≥ 12 weeks.",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0-2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0-2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* 20 years and older in Japan",
                "criterions": [
                    {
                        "exact_snippets": "20 years and older",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 20,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "in Japan",
                        "criterion": "location",
                        "requirement": {
                            "requirement_type": "country of residence",
                            "expected_value": "Japan"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "20 years and older",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 20,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "in Japan",
                        "criterion": "location",
                        "requirement": {
                            "requirement_type": "country of residence",
                            "expected_value": "Japan"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Radiographically measurable per RECIST v1.1.",
                "criterions": [
                    {
                        "exact_snippets": "Radiographically measurable per RECIST v1.1.",
                        "criterion": "disease measurability",
                        "requirement": {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Radiographically measurable per RECIST v1.1.",
                        "criterion": "disease measurability",
                        "requirement": {
                            "requirement_type": "assessment method",
                            "expected_value": "RECIST v1.1"
                        }
                    },
                    {
                        "exact_snippets": "Radiographically measurable per RECIST v1.1.",
                        "criterion": "disease measurability",
                        "requirement": {
                            "requirement_type": "assessment modality",
                            "expected_value": "radiographic"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Radiographically measurable per RECIST v1.1.",
                        "criterion": "disease measurability",
                        "requirement": {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Radiographically measurable per RECIST v1.1.",
                        "criterion": "disease measurability",
                        "requirement": {
                            "requirement_type": "assessment method",
                            "expected_value": "RECIST v1.1"
                        }
                    },
                    {
                        "exact_snippets": "Radiographically measurable per RECIST v1.1.",
                        "criterion": "disease measurability",
                        "requirement": {
                            "requirement_type": "assessment modality",
                            "expected_value": "radiographic"
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "* Prior receipt of a selective FGFR inhibitor.",
                "criterions": [
                    {
                        "exact_snippets": "Prior receipt of a selective FGFR inhibitor.",
                        "criterion": "selective FGFR inhibitor receipt",
                        "requirement": {
                            "requirement_type": "history of receipt",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Prior receipt of a selective FGFR inhibitor.",
                    "criterion": "selective FGFR inhibitor receipt",
                    "requirement": {
                        "requirement_type": "history of receipt",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Inability or unwillingness to swallow pemigatinib or significant gastrointestinal disorder(s) that could interfere with the absorption, metabolism, or excretion of pemigatinib.",
                "criterions": [
                    {
                        "exact_snippets": "Inability ... to swallow pemigatinib",
                        "criterion": "ability to swallow pemigatinib",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "unwillingness to swallow pemigatinib",
                        "criterion": "willingness to swallow pemigatinib",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "significant gastrointestinal disorder(s) that could interfere with the absorption, metabolism, or excretion of pemigatinib",
                        "criterion": "gastrointestinal disorder(s) interfering with pemigatinib pharmacokinetics",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "not_criteria": {
                            "exact_snippets": "Inability ... to swallow pemigatinib",
                            "criterion": "ability to swallow pemigatinib",
                            "requirement": {
                                "requirement_type": "ability",
                                "expected_value": true
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "unwillingness to swallow pemigatinib",
                            "criterion": "willingness to swallow pemigatinib",
                            "requirement": {
                                "requirement_type": "willingness",
                                "expected_value": true
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "significant gastrointestinal disorder(s) that could interfere with the absorption, metabolism, or excretion of pemigatinib",
                            "criterion": "gastrointestinal disorder(s) interfering with pemigatinib pharmacokinetics",
                            "requirement": {
                                "requirement_type": "presence",
                                "expected_value": false
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half-lives (whichever is shorter) before the first dose of study drug.",
                "criterions": [
                    {
                        "exact_snippets": "Use of any potent CYP3A4 inhibitors ... within 14 days or 5 half-lives (whichever is shorter) before the first dose of study drug.",
                        "criterion": "use of potent CYP3A4 inhibitors",
                        "requirement": {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 14,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Use of any potent CYP3A4 inducers ... within 14 days or 5 half-lives (whichever is shorter) before the first dose of study drug.",
                        "criterion": "use of potent CYP3A4 inducers",
                        "requirement": {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 14,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Use of any potent CYP3A4 inhibitors ... within 14 days or 5 half-lives (whichever is shorter) before the first dose of study drug.",
                        "criterion": "use of potent CYP3A4 inhibitors",
                        "requirement": {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 14,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Use of any potent CYP3A4 inducers ... within 14 days or 5 half-lives (whichever is shorter) before the first dose of study drug.",
                        "criterion": "use of potent CYP3A4 inducers",
                        "requirement": {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 14,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* Documented FGF/FGFR alteration and have either 1a) failed at least 1 previous treatment for their metastatic or surgically unresectable urothelial carcinoma (ie, chemotherapy, immunotherapy) or 1b) have not received chemotherapy due to poor ECOG status or 2) have insufficient renal function.",
                "criterions": [
                    {
                        "exact_snippets": "Documented FGF/FGFR alteration",
                        "criterion": "FGF/FGFR alteration",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Documented FGF/FGFR alteration",
                        "criterion": "FGF/FGFR alteration",
                        "requirement": {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "failed at least 1 previous treatment for their metastatic or surgically unresectable urothelial carcinoma (ie, chemotherapy, immunotherapy)",
                        "criterion": "previous treatment for metastatic or surgically unresectable urothelial carcinoma",
                        "requirement": {
                            "requirement_type": "number of failed treatments",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "treatment"
                            }
                        }
                    },
                    {
                        "exact_snippets": "failed at least 1 previous treatment for their metastatic or surgically unresectable urothelial carcinoma (ie, chemotherapy, immunotherapy)",
                        "criterion": "previous treatment for metastatic or surgically unresectable urothelial carcinoma",
                        "requirement": {
                            "requirement_type": "treatment type",
                            "expected_value": [
                                "chemotherapy",
                                "immunotherapy"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "have not received chemotherapy due to poor ECOG status",
                        "criterion": "chemotherapy receipt",
                        "requirement": {
                            "requirement_type": "received",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "poor ECOG status",
                        "criterion": "ECOG status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "poor"
                        }
                    },
                    {
                        "exact_snippets": "have insufficient renal function",
                        "criterion": "renal function",
                        "requirement": {
                            "requirement_type": "sufficiency",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Histologically documented metastatic or surgically unresectable urothelial carcinoma; may include primary site from urethra, ureters, upper tract, renal pelvis, and bladder.",
                "criterions": [
                    {
                        "exact_snippets": "Histologically documented metastatic or surgically unresectable urothelial carcinoma",
                        "criterion": "urothelial carcinoma",
                        "requirement": {
                            "requirement_type": "histological documentation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Histologically documented metastatic or surgically unresectable urothelial carcinoma",
                        "criterion": "urothelial carcinoma",
                        "requirement": {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "metastatic",
                                "surgically unresectable"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "may include primary site from urethra, ureters, upper tract, renal pelvis, and bladder",
                        "criterion": "primary tumor site",
                        "requirement": {
                            "requirement_type": "anatomic location",
                            "expected_value": [
                                "urethra",
                                "ureters",
                                "upper tract",
                                "renal pelvis",
                                "bladder"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}